+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Central Nervous System Biomarkers Market - Global Forecast 2026-2032- Product Image
Central Nervous System Biomarkers Market - Global Forecast 2026-2032- Product Image
New

Central Nervous System Biomarkers Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 195 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010785
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The central nervous system biomarkers market is undergoing rapid transformation as advances in molecular science, clinical validation, and health system integration converge to reshape diagnostics and therapeutic development for neurological and psychiatric disorders.

Market Snapshot

The Central Nervous System Biomarkers Market grew from USD 5.19 billion in 2025 to USD 5.54 billion in 2026. It is expected to progress at a CAGR of 7.89%, reaching USD 8.83 billion by 2032.

Scope & Segmentation

  • Biomarker Types: Includes genomic, proteomic, and metabolomic biomarkers, each requiring distinct discovery processes, analytical infrastructure, and validation strategies.
  • Disease Indications: Spans neurodegenerative disease, neurodevelopmental disorder, and psychotic disorder applications, each demanding tailored evaluation methods and clinical workflows.
  • Platform Technologies: Covers immunoassay, mass spectrometry, and next-generation sequencing platforms—each with unique strengths for clinical and translational settings.
  • Application Use-Cases: Encompasses diagnostic, therapeutic, drug discovery, personalized medicine, prognosis, and research & development contexts.
  • End-User Dynamics: Serves academic research institutes, healthcare providers, and pharmaceutical companies with diverse purchasing and adoption priorities.
  • Regions: Analyzes trends in the Americas, Europe, Middle East & Africa (EMEA), and Asia-Pacific, considering varying research investment, regulatory frameworks, and healthcare financing models.

Key Takeaways

  • Biomarkers are moving from academic research to routine clinical care, enabled by improved assay sensitivity and multiplexing capabilities.
  • Integration of computational methods with multi-omic and clinical datasets enhances diagnostic accuracy and supports the identification of new disease subtypes.
  • Cross-sector collaborations—including healthcare providers, life sciences firms, and regulatory specialists—streamline evidence generation and shape adoption pathways.
  • Evolving regulations and payer requirements are raising the bar for clinical utility, demanding transparent validation and robust real-world evidence.
  • Supply chain pressures, including tariffs and import restrictions, are influencing procurement strategies and elevating the need for supply resilience and local manufacturing partnerships.
  • Integrated assay-and-analytics offerings, supported by strong customer support infrastructures, drive long-term adoption among clinical stakeholders.

Tariff Impact

Shifts in tariffs and trade compliance directly affect the cost and availability of key laboratory instruments, reagents, and consumables essential for CNS biomarker development. These disruptions prompt organizations to diversify suppliers, leverage regional manufacturing, and buffer critical inventory. Adjusted operational timelines and strategic scenario planning are now vital to maintain momentum in biomarker discovery and clinical validation against a backdrop of global trade fluctuations.

Methodology & Data Sources

This analysis is built on structured interviews with clinicians, laboratory directors, industry executives, and regulatory advisors, validated through follow-up discussions and peer-reviewed literature. Regulatory guidance, public company disclosures, and clinical trial data supplement primary insights. Triangulation and scenario testing ensure findings reflect both reported capability and real-world practice, while domain experts review all conclusions for accuracy.

Why This Report Matters

  • Offers actionable intelligence to strengthen technology selection, clinical development planning, and commercialization strategy for senior decision-makers.
  • Provides clear segmentation and regional analysis to support targeted investment and competitive positioning.
  • Delivers evidence-based recommendations to mitigate supply chain, regulatory, and operational risks across multiple end-user environments.

Conclusion

Organizations investing in central nervous system biomarkers must align scientific rigor with operational agility and market insight to succeed. Those prioritizing resilience, interoperability, and validated evidence are well positioned to drive clinical adoption and improve patient outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Central Nervous System Biomarkers Market, by Type
8.1. Genomic Biomarkers
8.2. Metabolomic Biomarkers
8.3. Proteomic Biomarkers
9. Central Nervous System Biomarkers Market, by Disease Indication
9.1. Neurodegenerative Diseases
9.2. Neurodevelopmental Disorders
9.3. Psychotic Disorders
10. Central Nervous System Biomarkers Market, by Technology
10.1. Immunoassay
10.1.1. ELISA
10.1.2. Western Blot
10.2. Mass Spectrometry
10.2.1. Gas Chromatography Coupled
10.2.2. Liquid Chromatography Coupled
10.3. Next-Generation Sequencing
10.3.1. Targeted Sequencing
10.3.2. Whole Genome Sequencing
11. Central Nervous System Biomarkers Market, by Application
11.1. Diagnosis & Therapeutics
11.2. Drug Discovery & Development
11.3. Personalized Medicine
11.4. Prognosis
11.5. Research & Development
12. Central Nervous System Biomarkers Market, by End-User
12.1. Academic Research Institutes
12.2. Healthcare Providers
12.3. Pharmaceutical Companies
13. Central Nervous System Biomarkers Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Central Nervous System Biomarkers Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Central Nervous System Biomarkers Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Central Nervous System Biomarkers Market
17. China Central Nervous System Biomarkers Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. Abbvie Inc.
18.7. Acumen Pharmaceuticals Inc.
18.8. ADx NeuroSciences NV
18.9. Agilent Technologies, Inc.
18.10. Altoida
18.11. Becton, Dickinson and Company
18.12. Bio-Rad Laboratories, Inc.
18.13. BioMérieux SA
18.14. Bruker Corporation
18.15. C2N Diagnostics, LLC
18.16. Cerevance, LLC
18.17. Charles River Laboratories International, Inc.
18.18. Eli Lilly and Co.
18.19. F. Hoffmann-La Roche AG
18.20. Invicro LLC
18.21. Johnson & Johnson Services Inc.
18.22. Laboratory Corporation of America Holdings
18.23. Mediford Corporation
18.24. Merck & Co., Inc.
18.25. Myriad Genetics, Inc.
18.26. Neurotrack Technologies, Inc.
18.27. Novartis AG
18.28. Qiagen N.V.
18.29. Quanterix Corporation
18.30. Sanofi SA
18.31. Shimadzu Corporation
18.32. Siemens Healthineers
18.33. SynapCell
18.34. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 116. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 118. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 119. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 120. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 121. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 122. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 123. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 124. EUROPE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 125. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 127. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 134. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 135. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 136. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 137. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 138. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 139. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 140. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 141. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 142. AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 153. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 155. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 156. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 157. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 158. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 159. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 160. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 161. ASEAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 162. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 164. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 165. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 166. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 167. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 168. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 169. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 170. GCC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 180. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 182. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 183. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 184. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 185. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 186. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 187. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 188. BRICS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 189. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 191. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 192. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 193. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 194. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 195. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 196. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 197. G7 CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 198. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 200. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 201. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 202. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 203. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 204. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 205. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 206. NATO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 207. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 208. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 213. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
TABLE 217. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 219. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 220. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 221. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 222. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2032 (USD MILLION)
TABLE 223. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 224. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 225. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Central Nervous System Biomarkers market report include:
  • Abbott Laboratories
  • Abbvie Inc.
  • Acumen Pharmaceuticals Inc.
  • ADx NeuroSciences NV
  • Agilent Technologies, Inc.
  • Altoida
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMérieux SA
  • Bruker Corporation
  • C2N Diagnostics, LLC
  • Cerevance, LLC
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • Invicro LLC
  • Johnson & Johnson Services Inc.
  • Laboratory Corporation of America Holdings
  • Mediford Corporation
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Neurotrack Technologies, Inc.
  • Novartis AG
  • Qiagen N.V.
  • Quanterix Corporation
  • Sanofi SA
  • Shimadzu Corporation
  • Siemens Healthineers
  • SynapCell
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages195
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.54 Billion
Forecasted Market Value ( USD ) by 2032 $ 8.83 Billion
Compound Annual Growth Rate7.8%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Central Nervous System Biomarkers Market Report 2025 - Product Image

Central Nervous System Biomarkers Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Central Nervous System Biomarkers - Global Strategic Business Report - Product Image

Central Nervous System Biomarkers - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Global Central Nervous System Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Central Nervous System Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 115 Pages
  • Global
From
Brain Biomarkers Market - Global Forecast 2026-2032 - Product Image

Brain Biomarkers Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Biomarkers for Traumatic Brain Injury - Product Image

Biomarkers for Traumatic Brain Injury

  • Book

About the CNS Marker Market

Biomarkers are biological molecules that can be used to measure and monitor the progression of a disease or condition. The Central Nervous System (CNS) Marker market is a subset of the biomarker market that focuses on the development of biomarkers for neurological diseases and disorders. CNS Markers are used to diagnose, monitor, and treat neurological diseases and disorders, such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. They are also used to measure the effectiveness of treatments and to predict the risk of developing neurological diseases. CNS Markers are typically proteins, peptides, or metabolites that are found in the cerebrospinal fluid, blood, or other bodily fluids. They can be used to detect the presence of a neurological disorder, to monitor the progression of the disorder, and to measure the effectiveness of treatments. Some companies in the CNS Marker market include Bio-Rad Laboratories, Bio-Techne, and Abcam. Other companies include Bio-Techne, Abcam, and Bio-Rad Laboratories. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.